# Cell And Gene Therapy Manufacturing Service Market

> Cell and Gene Therapy Manufacturing Service Market Research Report By Service Type (Cell Therapy Manufacturing, Gene Therapy Manufacturing, Plasmid DNA Manufacturing), By Cell Type (T Cells, Stem Cells, B Cells, Natural Killer Cells), By Product Type (Autologous Products, Allogeneic Products, Gene Edited Products), By End Use (Pharmaceutical Companies, Biotechnology Companies, Academic Research Institutions, Contract Manufacturing Organizations) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 14.64%
- **2024:** $ 8.31 Billion
- **2025:** $ 9.53 Billion
- **2035:** $ 37.36 Billion
- **Key Players:** Lonza(CH), Catalent (US), WuXi AppTec (CN), Boehringer Ingelheim(DE), Thermo Fisher Scientific (US), Sartorius (DE), Miltenyi Biotec (DE), Celerion (US), Kite Pharma (US)

**Report ID:** MRFR/HC/40089-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/cell-and-gene-therapy-manufacturing-service-market-41753

---

## Market Summary

## **Cell and Gene Therapy Manufacturing Service Market Overview:**

As per MRFR analysis, the Cell and Gene Therapy Manufacturing Service Market Size was estimated at 7.25 (USD Billion) in 2023.The Cell and Gene Therapy Manufacturing Service Market Industry is expected to grow from 8.32(USD Billion) in 2024 to 37.4 (USD Billion) by 2035. The Cell and Gene Therapy Manufacturing Service Market CAGR (growth rate) is expected to be around 14.64% during the forecast period (2025 - 2035).

### **Key Cell and Gene Therapy Manufacturing Service Market Trends Highlighted**

The Global Cell and Gene Therapy Manufacturing Service Market is driven by several key factors. Increasing investment in research and development of advanced therapies, along with the rising prevalence of genetic disorders and chronic diseases, has significantly fueled demand for these services. The growing emphasis on personalized medicine, where treatments are tailored to individual genetic profiles, is also a critical driver.

Additionally, collaborations between biotech companies and academic institutions are enhancing innovation in this field. Regulatory support and advancements in manufacturing technology further contribute to the market's expansion. Numerous opportunities exist within the market that can be captured. There is a growing need for specialized facilities that can scale production effectively while ensuring compliance with regulatory standards. Companies can explore developing partnerships for technology transfer to enhance production capabilities.

Moreover, the demand for Contract Manufacturing Organizations (CMOs) that support small to mid-sized biotech firms is increasing, creating a niche for service providers to cater to these companies. Advances in automated manufacturing processes can boost efficiency and reduce costs, allowing opportunities for service providers to offer competitive pricing. Recent trends indicate a shift towards integrated service models that combine development and manufacturing. This approach streamlines the process and reduces time to market, appealing to biotech companies aiming for faster commercialization of their therapies.

Moreover, the rise of cell-based therapies, such as CAR T-cell therapy, showcases the potential for innovative treatment options. The focus on sustainability in manufacturing processes is gaining traction, prompting companies to explore green technologies that align with global environmental goals. Overall, the market is poised for growth, driven by innovation, collaboration, and an ever-expanding understanding of genetic medicine.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Cell and Gene Therapy Manufacturing Service Market Drivers**

### **Rising Investment in Biotechnology and Pharmaceuticals**

The Global Cell and Gene Therapy Manufacturing Service Sector is estimated to grow faster primarily because of the growing prospects in the biotechnology and pharmaceutical industries. Healthcare systems development and demand for better therapies is a driver for investment. Institutions, whether research or private firms are investing a lot in the development of gene and cell therapy markets.

As a result, there is a surge of funds that facilitate the invention of new therapies potentially capable of stopping or even curing a disease previously classified as untreatable. Greater levels of merger and acquisition activities observed in the biotechnology industry are a clear indication of the higher level of interest and concentration on gene and cell therapies. Furthermore, the development of new equipment to manufacture high-end systems that have enhanced throughput and performance also creates a good market for these therapies.

The therapies once they advance from the experimental stage into commercialization, can change treatment paradigms and create a competitive both demand and supply side within the Global Cell and Gene Therapy Manufacturing Service Sector.

### **Increasing Prevalence of Genetic Disorders**

The prevalence of genetic disorders, along with chronic diseases requiring innovative treatment solutions, acts as a significant driver for the Global Cell and Gene Therapy Manufacturing Service Market Industry. As more individuals are diagnosed with conditions that can be treated by advanced gene and cell therapies, there is an urgent need for manufacturing services capable of supporting their development and large-scale production. This demand highlights the need for specialized manufacturing processes that can deal with the complexities of gene therapy, such as vector production and cell culture systems.

The rise in genetic disorders underscores an overarching need for tailored therapeutic options, making the services offered by this market increasingly invaluable.

### **Technological Advancements in Manufacturing Processes**

Technological innovations in manufacturing processes significantly contribute to the growth of the Global Cell and Gene Therapy Manufacturing Service Market Industry. Emerging technologies, such as automation, artificial intelligence, and advanced bioprocessing techniques, streamline production and improve efficiency. These advancements not only enhance the quality of therapeutic products but also reduce production costs, making cell and gene therapies more accessible. As manufacturers adopt these technologies, they can better comply with regulatory requirements and ensure the scalability of production, further propelling market expansion.

## **Cell and Gene Therapy Manufacturing Service Market Segment Insights:**

### **Cell and Gene Therapy Manufacturing Service Market Service Type Insights   **

The Global Cell and Gene Therapy Manufacturing Service Market showcases a robust and expanding landscape driven by growing therapeutic needs and advancements in biomanufacturing technology. As of 2024, the market valuation stands at 8.32 USD Billion, with a significant growth trajectory projected up to 2035, when it is expected to reach 37.4 USD Billion. Within this market, the Service Type category has been segmented into Cell Therapy Manufacturing, Gene Therapy Manufacturing, and Plasmid DNA Manufacturing, each contributing to the overall market dynamics with varying significance and market share.

In 2024, the Cell Therapy Manufacturing market holds a valuation of 3.2 USD Billion, and by 2035, it is projected to increase to 13.8 USD Billion.

This segment plays a vital role in the development of regenerative medicine, focusing on treating diseases by repairing or replacing damaged cells. Its dominance is attributed to the rising prevalence of chronic diseases and advancements in cell-based therapies, which are gaining traction due to their targeted approach and potential for personalized medicine. Meanwhile, the Gene Therapy Manufacturing segment is valued at 4.0 USD Billion in 2024 and is expected to grow to 17.4 USD Billion by 2035, showcasing its significant presence in the market.

The demand for innovative treatments capable of addressing genetic disorders has propelled the development of this segment, where therapeutic products aim to correct defective genes responsible for disease development. The ongoing research and increased investments in gene editing technologies significantly bolster this segment's importance within the Global Cell and Gene Therapy Manufacturing Service Market as it captures a larger share and presents a promising future. Lastly, the Plasmid DNA Manufacturing segment, although smaller with a valuation of 1.12 USD Billion in 2024, is projected to grow to 6.2 USD Billion by 2035.

This segment is essential for the production of DNA-based vaccines and gene therapies. While it currently holds the least market share among its counterparts, its role cannot be underestimated as it underpins several key therapies and vaccines, particularly in response to emerging health threats and the growing field of DNA immunotherapy. Overall, the segmentation within the Global Cell and Gene Therapy Manufacturing Service Market underscores important growth areas, with Cell Therapy and Gene Therapy Manufacturing leading in terms of market appeal and relevance, reflecting major trends in healthcare innovation.

The comprehensive insights into each service type not only highlight their current contributions but also emphasize the overarching opportunities within the Global Cell and Gene Therapy Manufacturing Service Market, driven by the continued advancements in manufacturing technologies and the pressing need for efficient therapeutic solutions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Cell and Gene Therapy Manufacturing Service Market Cell Type Insights   **

The Global Cell and Gene Therapy Manufacturing Service Market is poised for significant growth, expected to reach a value of 8.32 USD Billion in 2024. This market exhibits a robust segmentation into various cell types, including T Cells, Stem Cells, B Cells, and Natural Killer Cells, each playing a critical role in therapeutic applications. T Cells, known for their ability to recognize and destroy infected or cancerous cells, have emerged as a cornerstone in immunotherapy, contributing to strong market growth.

Stem Cells are crucial for regenerative medicine and have versatile applications in treating various conditions, showcasing their importance in the market landscape.

B Cells, responsible for antibody production, are essential in battling infections and thus are seeing increased attention in therapy development. Natural Killer Cells, recognized for their rapid response to virally infected cells and tumors, are gaining traction due to their potential in innovative treatments. The Global Cell and Gene Therapy Manufacturing Service Market data reveal a trend towards expanding research and production capabilities, driven by the rise in chronic diseases and advancements in genetic engineering techniques. Such dynamics present opportunities for stakeholders while also highlighting challenges related to regulatory compliance and manufacturing scalability.

### **Cell and Gene Therapy Manufacturing Service Market Product Type Insights   **

The Global Cell and Gene Therapy Manufacturing Service Market is experiencing notable growth driven by the increasing demand for innovative therapies, with a projected value of 8.32 billion USD by 2024. The market segmentation highlights various product types, specifically Autologous Products, Allogeneic Products, and Gene-Edited Products, which play critical roles in addressing diverse patient needs. Autologous Products are significant as they utilize a patient’s own cells, minimizing the risk of rejection and improving therapeutic outcomes.

Conversely, Allogeneic Products derived from donor cells dominate the market due to their broad applicability and efficiency in large-scale production. Gene Edited Products are also becoming increasingly important, offering advanced precision in treating genetic disorders. Together, these product types not only contribute to the overall Global Cell and Gene Therapy Manufacturing Service Market revenue but also reflect the innovation and growth potential within the industry. The combination of advanced technologies and the increasing focus on personalized medicine presents numerous opportunities while also bringing challenges, such as regulatory hurdles and production complexities, that need to be navigated for sustained market growth.

### **Cell and Gene Therapy Manufacturing Service Market End Use Insights   **

The Global Cell and Gene Therapy Manufacturing Service Market is a dynamic sector, expected to reach a valuation of 8.32 billion USD in 2024, illustrating significant growth potential. The segmentation of the market by End Use reveals various sectors, each playing a vital role in market expansion. Pharmaceutical companies remain a significant force as they drive the development and commercialization of innovative therapies, responding to urgent medical needs. Similarly, biotechnology companies dominate due to their focus on research and development, harnessing advancements in gene editing and cell therapy.

Academic research institutions contribute crucial insights and advancements through studies and trials, fostering innovation in therapy manufacturing processes. [Contract manufacturing organizations](../../../reports/contract-manufacturing-organization-market-41474) (CMOs) are becoming increasingly important as they provide essential support services, enhancing efficiency and reducing time to market for biopharmaceutical products. The collective efforts of these segments facilitate the overall growth of the Global Cell and Gene Therapy Manufacturing Service Market, reflecting a robust industry poised for expansion, driven by trends such as increased R spending and the rising prevalence of genetic disorders.

### **Cell and Gene Therapy Manufacturing Service Market Regional Insights   **

The Global Cell and Gene Therapy Manufacturing Service Market shows significant growth within the Regional segment, with a noteworthy valuation of 8.32 USD Billion in 2024. North America holds a majority share, valued at 4.2 USD Billion, accounting for more than half of the market's financial dynamics due to its advanced healthcare infrastructure and robust investment in biotechnology. Europe follows with a valuation of 2.0 USD Billion, reflecting its strong regulatory frameworks and a growing number of clinical trials focusing on gene therapies.

APAC is valued at 1.8 USD Billion, showcasing promising growth opportunities triggered by increasing healthcare spending and research initiatives in the region. South America and MEA, holding values of 0.6 USD Billion and 0.72 USD Billion, respectively, are the smaller markets but demonstrate potential due to developing healthcare systems and rising interest in innovative treatment options. The variations in market valuation highlight the dominance of North America in this industry while underlining the emerging opportunities in APAC, South America, and MEA, contributing to the overall expansion of the Global Cell and Gene Therapy Manufacturing Service Market.

  Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Cell and Gene Therapy Manufacturing Service Market Key Players and Competitive Insights:**

The Global Cell and Gene Therapy Manufacturing Service Market has witnessed considerable growth and transformation, driven by advancements in biotechnology and increasing investments in research and development. The competitive landscape is characterized by a mix of established companies and new entrants, all striving to capture market share and innovate within this burgeoning sector. Key competitive insights indicate a strong focus on technological advancements, regulatory compliance, and partnerships with research institutions to enhance service offerings.

Companies are leveraging their capabilities in process development, quality assurance, and scale-up manufacturing to meet the rising demand for personalized medicine and advanced therapeutic solutions. The market's competitiveness is further intensified by the need for companies to establish their presence globally and respond to regional regulations effectively while maintaining operational efficiency.

AbbVie has established itself as a significant player in the Global Cell and Gene Therapy Manufacturing Service Market due to its extensive portfolio of biopharmaceuticals and commitment to research and development. The company's strength lies in its robust capabilities in manufacturing processes and quality control, ensuring that its gene and cell therapies meet stringent regulatory requirements. AbbVie’s strategic collaborations with various research institutes and academic organizations have enabled it to harness cutting-edge technologies and foster innovation in therapeutic development. Furthermore, the company benefits from a well-established global presence, allowing it to effectively distribute its services worldwide.

This strategic positioning, coupled with strong financial backing and a focus on patient-centered solutions, enhances AbbVie’s competitive edge in the cell and gene therapy space. Thermo Fisher Scientific is another notable player in the Global Cell and Gene Therapy Manufacturing Service Market, recognized for its comprehensive portfolio of end-to-end solutions supporting gene and cell therapy development. The company offers a wide range of services, including plasmid DNA manufacturing, viral vector production, and cell banking, catering to the unique needs of biopharmaceutical companies engaged in the production of advanced therapies.

Thermo Fisher's emphasis on innovation and technology integration has positioned it as a trusted partner in the manufacturing arena, allowing clients to streamline processes and improve production efficiency.

The company's commitment to providing tailored solutions and its strong customer support network are key strengths that contribute to its competitive stature. Additionally, Thermo Fisher’s global footprint and extensive resources enable it to capitalize on emerging trends within the cell and gene therapy landscape, thereby reinforcing its market leadership.

### **Key Companies in the Cell and Gene Therapy Manufacturing Service Market Include:**

- AbbVie
- Thermo Fisher Scientific
- Novartis
- Boehringer Ingelheim
- Catalent
- [Charles River Laboratories](https://www.criver.com/products-services/cell-and-gene-therapy-cdmo-solutions/cell-therapy-manufacturing)
- Samsung Biologics
- AstraZeneca
- Lonza
- GenScript
- WuXi AppTec
- Vector BioPharma
- Miltenyi Biotec
- Amgen
- Kite Pharma

## **Cell And Gene Therapy Manufacturing Service Industry Developments**

- **Q2 2024: FUJIFILM Diosynth Biotechnologies Opens New Cell and Gene Therapy Manufacturing Facility in Texas** FUJIFILM Diosynth Biotechnologies announced the opening of its new state-of-the-art cell and gene therapy manufacturing facility in College Station, Texas, expanding its capacity to support clinical and commercial manufacturing for advanced therapies.
- **Q2 2024: Lonza Expands Cell and Gene Therapy Manufacturing Capabilities with New Suite in Houston** Lonza announced the launch of a new manufacturing suite at its Houston facility, designed to increase capacity for viral vector production and support growing demand from cell and gene therapy developers.
- **Q2 2024: Catalent Acquires Cell and Gene Therapy Manufacturing Site from Erytech Pharma** Catalent completed the acquisition of Erytech Pharma’s cell and gene therapy manufacturing facility in Princeton, New Jersey, enhancing its North American manufacturing footprint for advanced therapies.
- **Q2 2024: Oxford Biomedica and Homology Medicines Announce Strategic Manufacturing Partnership** Oxford Biomedica and Homology Medicines entered a multi-year partnership to leverage Oxford Biomedica’s viral vector manufacturing expertise for Homology’s gene therapy pipeline.
- **Q3 2024: Thermo Fisher Scientific Launches New Commercial Packaging Services for Cell and Gene Therapies** Thermo Fisher Scientific introduced Patheon Commercial Packaging Services in the US and Europe, offering integrated logistics, serialization, and global distribution for cell and gene therapy products.
- **Q3 2024: AGC Biologics Opens New Viral Vector Manufacturing Facility in Milan** AGC Biologics inaugurated a new viral vector manufacturing facility in Milan, Italy, to meet increasing demand for gene therapy manufacturing services in Europe.
- **Q3 2024: Takara Bio Expands Cell Therapy Manufacturing Operations in Shiga, Japan** Takara Bio announced the expansion of its cell therapy manufacturing operations in Shiga, Japan, adding new cleanroom suites and increasing production capacity for clinical and commercial supply.
- **Q4 2024: Catalent Wins Major Manufacturing Contract for Commercial Supply of CAR-T Therapy** Catalent secured a multi-year contract to manufacture a commercial CAR-T cell therapy for a leading biopharmaceutical company, strengthening its position in the cell therapy manufacturing market.
- **Q4 2024: Lonza Appoints New Head of Cell and Gene Therapy Manufacturing Division** Lonza announced the appointment of a new executive to lead its global cell and gene therapy manufacturing division, aiming to accelerate growth and innovation in advanced therapy production.
- **Q1 2025: Oxford Biomedica Acquires Viral Vector Manufacturing Assets from Cellectis** Oxford Biomedica completed the acquisition of viral vector manufacturing assets from Cellectis, expanding its capabilities in gene therapy manufacturing and strengthening its European operations.
- **Q2 2025: FUJIFILM Irvine Scientific Opens New Cell Culture Media Manufacturing Facility in the Netherlands** FUJIFILM Irvine Scientific opened a new facility in Tilburg, Netherlands, dedicated to the production of cell culture media for cell and gene therapy manufacturing, supporting European and global clients.
- **Q2 2025: SGS SA Launches Expanded Cell and Gene Therapy Testing Services in North America** SGS SA announced the launch of expanded analytical and quality control testing services for cell and gene therapy products at its North American laboratories, supporting regulatory compliance and product release.

## **Cell and Gene Therapy Manufacturing Service Market Segmentation Insights**

### **Cell and Gene Therapy Manufacturing Service Market Service Type Outlook**

- Cell Therapy Manufacturing
- Gene Therapy Manufacturing
- Plasmid DNA Manufacturing

### **Cell and Gene Therapy Manufacturing Service Market Cell Type Outlook**

- T Cells
- Stem Cells
- B Cells
- Natural Killer Cells

### **Cell and Gene Therapy Manufacturing Service Market Product Type Outlook**

- Autologous Products
- Allogeneic Products
- Gene Edited Products

### **Cell and Gene Therapy Manufacturing Service Market End Use Outlook**

- Pharmaceutical Companies
- Biotechnology Companies
- Academic Research Institutions
- Contract Manufacturing Organizations

### **Cell and Gene Therapy Manufacturing Service Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Regulatory Support and Frameworks

The establishment of supportive regulatory frameworks is crucial for the Cell and Gene Therapy Manufacturing Service Market. Regulatory bodies are increasingly recognizing the potential of gene and cell therapies, leading to expedited approval processes and guidelines that facilitate innovation. For instance, the introduction of programs like the FDA's Breakthrough Therapy Designation has accelerated the development of promising therapies. This regulatory support encourages investment in manufacturing capabilities, as companies seek to navigate the complex landscape of compliance while bringing novel therapies to market. As a result, the Cell and Gene Therapy Manufacturing Service Market is likely to experience robust growth driven by these favorable regulatory conditions.

### Rising Prevalence of Genetic Disorders

The increasing incidence of genetic disorders is a pivotal driver for the Cell and Gene Therapy Manufacturing Service Market. As more individuals are diagnosed with conditions such as hemophilia, muscular dystrophy, and various inherited diseases, the demand for innovative therapies rises. According to recent estimates, genetic disorders affect approximately 1 in 10 individuals, underscoring the urgent need for effective treatments. This growing patient population propels investments in research and development, leading to a surge in the production of gene therapies. Consequently, manufacturers are compelled to enhance their capabilities to meet the escalating demand for tailored therapeutic solutions, thereby driving growth in the Cell and Gene Therapy Manufacturing Service Market.

### Increased Investment in Biopharmaceuticals

The surge in investment within the biopharmaceutical sector significantly influences the Cell and Gene Therapy Manufacturing Service Market. Venture capital and private equity funding have seen remarkable increases, with billions allocated to companies focused on gene and cell therapies. This influx of capital not only supports research and development but also enhances manufacturing capabilities, allowing for the scaling of production processes. As biopharmaceutical companies expand their portfolios to include gene therapies, the demand for specialized manufacturing services rises. This trend indicates a promising trajectory for the Cell and Gene Therapy Manufacturing Service Market, as financial backing fuels innovation and operational expansion.

### Technological Advancements in Gene Editing

Technological innovations, particularly in gene editing techniques like CRISPR and TALEN, are transforming the landscape of the Cell and Gene Therapy Manufacturing Service Market. These advancements enable precise modifications to genetic material, facilitating the development of targeted therapies. The global market for gene editing technologies is projected to reach substantial figures, reflecting the increasing adoption of these methods in therapeutic applications. As researchers and manufacturers harness these technologies, the efficiency and effectiveness of gene therapies improve, leading to a broader acceptance and integration into clinical practice. This trend not only enhances the therapeutic potential but also stimulates the growth of the Cell and Gene Therapy Manufacturing Service Market.

### Growing Patient Demand for Innovative Therapies

The rising patient demand for innovative therapies is a driving force in the Cell and Gene Therapy Manufacturing Service Market. Patients increasingly seek advanced treatment options that offer potential cures for previously untreatable conditions. This shift in patient expectations is prompting healthcare providers to explore and adopt gene therapies, which are often seen as a last resort for severe diseases. Market Research Future indicates that the willingness to pay for these therapies is high, reflecting the perceived value of innovative solutions. As patient advocacy groups and healthcare professionals promote awareness of gene therapies, the demand for manufacturing services tailored to these products is likely to escalate, further propelling the growth of the Cell and Gene Therapy Manufacturing Service Market.

## Future Outlook

The Cell and Gene Therapy Manufacturing Service Market is projected to grow at a 14.64% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for personalized medicine, and regulatory support.

**New opportunities:**

- Expansion of automated manufacturing platforms for scalability Development of modular cleanroom solutions for cost efficiency Investment in AI-driven analytics for process optimization

By 2035, the market is expected to be robust, driven by innovation and strategic investments.

## Segment Insights

### By Service Type: Cell Therapy Manufacturing (Largest) vs. Gene Therapy Manufacturing (Fastest-Growing)

In the Cell and Gene Therapy Manufacturing Service Market, Cell Therapy Manufacturing remains the largest segment, capturing the significant share of the market, driven by its established applications in treating various diseases, including cancer and autoimmune disorders. Meanwhile, Gene Therapy Manufacturing is rapidly gaining traction, highlighting its potential in addressing genetic disorders and presenting a growing interest from both biopharmaceutical companies and investors due to its innovative treatment capabilities.

Service Type: Cell Therapy Manufacturing (Dominant) vs. Gene Therapy Manufacturing (Emerging)

Cell Therapy Manufacturing is characterized by its extensive application in regenerative medicine, primarily focused on the production of living cells for therapeutic use. This segment has demonstrated dominance in the market, benefiting from advanced technologies and increasing investment from biopharmaceutical firms, further solidifying its position in clinical settings. In contrast, Gene Therapy Manufacturing represents an emerging frontier marked by innovative techniques aimed at correcting defective genes. As regulatory frameworks evolve and technologies mature, this segment is experiencing rapid growth, attracting stakeholders keen on harnessing its vast potential for treating a variety of inherited and acquired conditions.

### By Cell Type: T Cells (Largest) vs. Stem Cells (Fastest-Growing)

In the Cell and Gene Therapy Manufacturing Service Market, T Cells currently represent the largest share among various cell types, driven by their established application in immunotherapy. Following closely, Stem Cells are rapidly gaining traction due to their versatility and potential in regenerative medicine applications. This dynamic distribution indicates a strong preference for T Cells in current therapeutic practices while highlighting the increasing interest and investment in Stem Cell research and development. Growth trends within this segment are predominantly influenced by advancements in biotechnology and an expanding clinical pipeline. T Cells are experiencing sustained success in cancer therapies, propelling their dominance. Conversely, Stem Cells are classified as the fastest-growing segment, fueled by innovative approaches in treating spinal cord injuries and degenerative diseases, indicating a shift towards personalized medicine solutions in the future.

T Cells (Dominant) vs. Stem Cells (Emerging)

T Cells are a dominant force in the Cell and Gene Therapy Manufacturing Service Market, primarily utilized in therapies aimed at treating various cancers and infectious diseases. Their strong performance is anchored on their ability to be engineered for enhanced efficacy, making them a preferred choice by researchers and clinicians alike. In contrast, Stem Cells represent an emerging segment with enormous potential due to their ability to differentiate into various cell types and repair damaged tissues. The regenerative capabilities of Stem Cells open avenues for groundbreaking treatments in conditions such as heart diseases and diabetes, positioning them as a pivotal area of research. As innovation continues, both T Cells and Stem Cells will shape the landscape of future therapeutic options.

### By Product Type: Autologous Products (Largest) vs. Allogeneic Products (Fastest-Growing)

In the Cell and Gene Therapy Manufacturing Service Market, autologous products dominate the landscape with a substantial share, primarily due to their personalized nature and effectiveness in treating various diseases. These therapies, derived from a patient’s own cells, continue to gain traction among healthcare providers and patients alike, establishing a solid market position. Conversely, allogeneic products are emerging rapidly, fueled by advancements in manufacturing processes and the demand for off-the-shelf solutions that provide broader accessibility and reduce treatment times. They are projected to experience substantial growth as technologies advance and more therapeutic applications are discovered.

Products: Autologous (Dominant) vs. Allogeneic (Emerging)

Autologous products, tailored to individual patients, represent the cornerstone of cell and gene therapy, showcasing remarkable clinical outcomes and personalized treatment plans. Their dominance lies in the precision of using the patient's own cells, resulting in fewer complications and higher acceptance. In contrast, allogeneic products, sourced from healthy donors, are gaining momentum as they offer immediate availability and can treat multiple patients simultaneously, addressing the market's urgent needs. This category is characterized by innovations aimed at scale-up production and diverse therapeutic applications, positioning it as the most promising segment in the near future. Together, these products illustrate the dynamic evolution of the Cell and Gene Therapy Manufacturing Service Market.

### By End Use: Pharmaceutical Companies (Largest) vs. Biotechnology Companies (Fastest-Growing)

The Cell and Gene Therapy Manufacturing Service Market is primarily dominated by Pharmaceutical Companies, which account for the largest share of the market. These companies leverage their extensive resources, established distribution channels, and regulatory experience to drive advancements in gene and cell therapies. In contrast, Biotechnology Companies have emerged as a rapidly growing segment, reflecting their innovative approaches, agility in research, and specialized focus on developing cutting-edge therapies at a faster pace compared to their pharmaceutical counterparts. The growth trend in this market is significantly influenced by factors such as increasing investment in gene and cell therapy research, collaborations between pharmaceutical and biotechnology firms, and the rising prevalence of chronic diseases. As Biotechnology Companies continue to experience robust growth, their ability to adapt to market demands and push the boundaries of therapeutic possibilities positions them well in the dynamic landscape of cell and gene therapies, creating a competitive environment that propels industry advancements.

Pharmaceutical Companies (Dominant) vs. Biotechnology Companies (Emerging)

Pharmaceutical Companies represent the dominant force in the Cell and Gene Therapy Manufacturing Service Market. Their established infrastructure, wide-ranging expertise, and extensive resources enable them to lead in commercialization and production capacities. These companies typically invest heavily in R&D, allowing them to stay at the forefront of innovative therapies. On the other hand, Biotechnology Companies are often viewed as the emerging challengers in this landscape. They are defined by their focus on specialized treatments and agility in adapting to technological advancements. Their emphasis on innovative approaches and partnerships with academic institutions makes them critical players, driving forward the development of novel therapies and expanding the scope of cell and gene treatments.

## Regional Market Share Analysis

The Global Cell and Gene Therapy Manufacturing Service Market shows significant growth within the Regional segment, with a noteworthy valuation of 8.32 USD Billion in 2024. North America holds a majority share, valued at 4.2 USD Billion, accounting for more than half of the market's financial dynamics due to its advanced healthcare infrastructure and robust investment in biotechnology. Europe follows with a valuation of 2.0 USD Billion, reflecting its strong regulatory frameworks and a growing number of clinical trials focusing on gene therapies.

APAC is valued at 1.8 USD Billion, showcasing promising growth opportunities triggered by increasing healthcare spending and research initiatives in the region. South America and MEA, holding values of 0.6 USD Billion and 0.72 USD Billion, respectively, are the smaller markets but demonstrate potential due to developing healthcare systems and rising interest in innovative treatment options. The variations in market valuation highlight the dominance of North America in this industry while underlining the emerging opportunities in APAC, South America, and MEA, contributing to the overall expansion of the Global Cell and Gene Therapy Manufacturing Service Market.

  Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## Competitive Benchmarking

The Global Cell and Gene Therapy Manufacturing Service Market has witnessed considerable growth and transformation, driven by advancements in biotechnology and increasing investments in research and development. The competitive landscape is characterized by a mix of established companies and new entrants, all striving to capture market share and innovate within this burgeoning sector. Key competitive insights indicate a strong focus on technological advancements, regulatory compliance, and partnerships with research institutions to enhance service offerings.Companies are leveraging their capabilities in process development, quality assurance, and scale-up manufacturing to meet the rising demand for personalized medicine and advanced therapeutic solutions. The market's competitiveness is further intensified by the need for companies to establish their presence globally and respond to regional regulations effectively while maintaining operational efficiency.AbbVie has established itself as a significant player in the Global Cell and Gene Therapy Manufacturing Service Market due to its extensive portfolio of biopharmaceuticals and commitment to research and development. The company's strength lies in its robust capabilities in manufacturing processes and quality control, ensuring that its gene and cell therapies meet stringent regulatory requirements. AbbVie’s strategic collaborations with various research institutes and academic organizations have enabled it to harness cutting-edge technologies and foster innovation in therapeutic development. Furthermore, the company benefits from a well-established global presence, allowing it to effectively distribute its services worldwide.This strategic positioning, coupled with strong financial backing and a focus on patient-centered solutions, enhances AbbVie’s competitive edge in the cell and gene therapy space. Thermo Fisher Scientific is another notable player in the Global Cell and Gene Therapy Manufacturing Service Market, recognized for its comprehensive portfolio of end-to-end solutions supporting gene and cell therapy development. The company offers a wide range of services, including plasmid DNA manufacturing, viral vector production, and cell banking, catering to the unique needs of biopharmaceutical companies engaged in the production of advanced therapies.Thermo Fisher's emphasis on innovation and technology integration has positioned it as a trusted partner in the manufacturing arena, allowing clients to streamline processes and improve production efficiency.The company's commitment to providing tailored solutions and its strong customer support network are key strengths that contribute to its competitive stature. Additionally, Thermo Fisher’s global footprint and extensive resources enable it to capitalize on emerging trends within the cell and gene therapy landscape, thereby reinforcing its market leadership.

## Recent News & Developments

- **Q2 2024: FUJIFILM Diosynth Biotechnologies Opens New Cell and Gene Therapy Manufacturing Facility in Texas** FUJIFILM Diosynth Biotechnologies announced the opening of its new state-of-the-art cell and gene therapy manufacturing facility in College Station, Texas, expanding its capacity to support clinical and commercial manufacturing for advanced therapies.
- **Q2 2024: Lonza Expands Cell and Gene Therapy Manufacturing Capabilities with New Suite in Houston** Lonza announced the launch of a new manufacturing suite at its Houston facility, designed to increase capacity for viral vector production and support growing demand from cell and gene therapy developers.
- **Q2 2024: Catalent Acquires Cell and Gene Therapy Manufacturing Site from Erytech Pharma** Catalent completed the acquisition of Erytech Pharma’s cell and gene therapy manufacturing facility in Princeton, New Jersey, enhancing its North American manufacturing footprint for advanced therapies.
- **Q2 2024: Oxford Biomedica and Homology Medicines Announce Strategic Manufacturing Partnership** Oxford Biomedica and Homology Medicines entered a multi-year partnership to leverage Oxford Biomedica’s viral vector manufacturing expertise for Homology’s gene therapy pipeline.
- **Q3 2024: Thermo Fisher Scientific Launches New Commercial Packaging Services for Cell and Gene Therapies** Thermo Fisher Scientific introduced Patheon Commercial Packaging Services in the US and Europe, offering integrated logistics, serialization, and global distribution for cell and gene therapy products.
- **Q3 2024: AGC Biologics Opens New Viral Vector Manufacturing Facility in Milan** AGC Biologics inaugurated a new viral vector manufacturing facility in Milan, Italy, to meet increasing demand for gene therapy manufacturing services in Europe.
- **Q3 2024: Takara Bio Expands Cell Therapy Manufacturing Operations in Shiga, Japan** Takara Bio announced the expansion of its cell therapy manufacturing operations in Shiga, Japan, adding new cleanroom suites and increasing production capacity for clinical and commercial supply.
- **Q4 2024: Catalent Wins Major Manufacturing Contract for Commercial Supply of CAR-T Therapy** Catalent secured a multi-year contract to manufacture a commercial CAR-T cell therapy for a leading biopharmaceutical company, strengthening its position in the cell therapy manufacturing market.
- **Q4 2024: Lonza Appoints New Head of Cell and Gene Therapy Manufacturing Division** Lonza announced the appointment of a new executive to lead its global cell and gene therapy manufacturing division, aiming to accelerate growth and innovation in advanced therapy production.
- **Q1 2025: Oxford Biomedica Acquires Viral Vector Manufacturing Assets from Cellectis** Oxford Biomedica completed the acquisition of viral vector manufacturing assets from Cellectis, expanding its capabilities in gene therapy manufacturing and strengthening its European operations.
- **Q2 2025: FUJIFILM Irvine Scientific Opens New Cell Culture Media Manufacturing Facility in the Netherlands** FUJIFILM Irvine Scientific opened a new facility in Tilburg, Netherlands, dedicated to the production of cell culture media for cell and gene therapy manufacturing, supporting European and global clients.
- **Q2 2025: SGS SA Launches Expanded Cell and Gene Therapy Testing Services in North America** SGS SA announced the launch of expanded analytical and quality control testing services for cell and gene therapy products at its North American laboratories, supporting regulatory compliance and product release.

## Report Scope

| MARKET SIZE 2024 | 8.311(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 9.528(USD Billion) |
| MARKET SIZE 2035 | 37.36(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 14.64% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Lonza (CH), Catalent (US), WuXi AppTec (CN), Boehringer Ingelheim (DE), Thermo Fisher Scientific (US), Sartorius (DE), Miltenyi Biotec (DE), Celerion (US), Kite Pharma (US) |
| Segments Covered | Service Type, Cell Type, Product Type, End Use, Regional |
| Key Market Opportunities | Advancements in personalized medicine drive demand for innovative Cell and Gene Therapy Manufacturing Service solutions. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the Cell and Gene Therapy Manufacturing Service Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for the Cell and Gene Therapy Manufacturing Service Market in 2035?**
A: The projected market valuation for the Cell and Gene Therapy Manufacturing Service Market in 2035 is 37.36 USD Billion.

**Q: What was the market valuation for the Cell and Gene Therapy Manufacturing Service Market in 2024?**
A: The market valuation for the Cell and Gene Therapy Manufacturing Service Market in 2024 was 8.311 USD Billion.

**Q: What is the expected CAGR for the Cell and Gene Therapy Manufacturing Service Market from 2025 to 2035?**
A: The expected CAGR for the Cell and Gene Therapy Manufacturing Service Market during the forecast period 2025 - 2035 is 14.64%.

**Q: Which companies are considered key players in the Cell and Gene Therapy Manufacturing Service Market?**
A: Key players in the market include Lonza, Catalent, WuXi AppTec, Boehringer Ingelheim, Thermo Fisher Scientific, Sartorius, Miltenyi Biotec, Celerion, and Kite Pharma.

**Q: What are the projected revenues for Cell Therapy Manufacturing by 2035?**
A: The projected revenue for Cell Therapy Manufacturing is expected to reach 11.5 USD Billion by 2035.

**Q: How does the market for Gene Therapy Manufacturing compare to Cell Therapy Manufacturing in 2035?**
A: By 2035, the market for Gene Therapy Manufacturing is projected to reach 15.0 USD Billion, surpassing the Cell Therapy Manufacturing market.

**Q: What is the expected revenue for Autologous Products in the Cell and Gene Therapy Manufacturing Service Market by 2035?**
A: The expected revenue for Autologous Products is projected to be 16.5 USD Billion by 2035.

**Q: What segment is anticipated to have the highest revenue growth in the Cell and Gene Therapy Manufacturing Service Market?**
A: The segment of Gene Therapy Manufacturing is anticipated to have the highest revenue growth, reaching 15.0 USD Billion by 2035.

**Q: What is the projected revenue for T Cells in the Cell and Gene Therapy Manufacturing Service Market by 2035?**
A: The projected revenue for T Cells is expected to reach 11.5 USD Billion by 2035.

**Q: Which end-use segment is expected to generate the highest revenue by 2035?**
A: The end-use segment of Pharmaceutical Companies is expected to generate the highest revenue, projected at 16.5 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/cell-and-gene-therapy-manufacturing-service-market-41753*